Dupont Capital Management Corp cut its holdings in shares of Catalent Inc (NYSE:CTLT) by 21.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,287 shares of the company’s stock after selling 3,348 shares during the quarter. Dupont Capital Management Corp’s holdings in Catalent were worth $499,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Catalent by 29.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after buying an additional 1,819,020 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Catalent by 234.5% during the 3rd quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock worth $3,740,000 after buying an additional 57,562 shares during the last quarter. TIAA CREF Investment Management LLC lifted its holdings in Catalent by 82.4% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 729,734 shares of the company’s stock worth $33,239,000 after buying an additional 329,560 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Catalent by 36.0% during the 3rd quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock worth $4,997,000 after buying an additional 29,008 shares during the last quarter. Finally, Morgan Stanley lifted its holdings in Catalent by 11.4% during the 3rd quarter. Morgan Stanley now owns 266,837 shares of the company’s stock worth $12,154,000 after buying an additional 27,250 shares during the last quarter. 96.85% of the stock is currently owned by institutional investors.
CTLT has been the topic of a number of research analyst reports. Morgan Stanley increased their target price on Catalent from $46.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, April 16th. First Analysis reaffirmed an “outperform” rating and set a $49.00 target price on shares of Catalent in a report on Tuesday, March 5th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Wednesday, February 6th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Monday, April 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Catalent has an average rating of “Buy” and a consensus price target of $49.57.
Shares of NYSE CTLT opened at $44.77 on Friday. The company has a market capitalization of $6.52 billion, a P/E ratio of 28.16, a P/E/G ratio of 2.38 and a beta of 1.70. Catalent Inc has a 12-month low of $29.23 and a 12-month high of $47.04. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.63 and a current ratio of 2.18.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.07. The business had revenue of $617.50 million for the quarter, compared to the consensus estimate of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The business’s revenue was down 1.7% on a year-over-year basis. During the same quarter last year, the business posted $0.41 EPS. On average, research analysts forecast that Catalent Inc will post 1.69 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Dupont Capital Management Corp Sells 3,348 Shares of Catalent Inc (CTLT)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/12/dupont-capital-management-corp-sells-3348-shares-of-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Is a Roth IRA right for you?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.